Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 May;62(5):759-65.
doi: 10.1002/pbc.25340. Epub 2014 Dec 2.

Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group

Daniel M Lerman  1 , Michael J Monument, Elizabeth McIlvaine, Xiao-qiong Liu, Dali Huang, Laura Monovich, Natalie Beeler, Richard G Gorlick, Neyssa M Marina, Richard B Womer, Julia A Bridge, Mark D Krailo, R Lor Randall, Stephen L Lessnick; Children's Oncology Group Ewing Sarcoma Biology Committee
Affiliations
Clinical Trial

Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group

Daniel M Lerman et al. Pediatr Blood Cancer. 2015 May.

Abstract

Background: A growing collection of retrospective studies have suggested that TP53 mutations and/or CDKN2A deletions have prognostic significance in Ewing sarcoma. We sought to evaluate these variables in patients with localized disease treated prospectively on a single Children's Oncology Group protocol.

Procedure: Of the 568 patients enrolled on Children's Oncology Group protocol AEWS0031 (NCT00006734), 112 had tumor specimens of sufficient quality and quantity to allow for analysis of TP53 mutations status by DNA sequencing, and CDKN2A deletion by dual color fluorescent in situ hybridization.

Results: Eight of 93 cases (8.6%) were found to have TP53 point mutations and 12 of 107 cases (11.2%) demonstrated homozygous CDKN2A deletion. Two cases were found to have an alteration in both genes. There was no significant difference in event-free survival of patients with TP53 mutations and/or CDKN2A deletions compared to patients with normal TP53/CDKN2A gene status, as demonstrated by log rank test (p = 0.58).

Conclusions: Although previous retrospective studies suggest their significance, TP53 mutation and/or CDKN2A deletion are not reliable prognostic biomarkers in localized Ewing sarcoma.

Keywords: Ewing sarcoma; biomarker; outcomes; prognosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram demonstrating patient specimen inclusion. SF= snap frozen, OCT= optimal cutting temperature, FFPE= formalin-fixed paraffin-embedded.
Figure 2
Figure 2
A. Kaplan-Meier EFS curve of evaluated (included) v. not evaluated (excluded) patients from protocol AEWS0031. B. Kaplan-Meier EFS curve of patients with v. without TP53 mutation. C. Kaplan-Meier EFS curve of patients with v. without CDKN2A deletion. D. Kaplan-Meier EFS curve of patients with v. without TP53 mutation and/or CDKN2A deletion
See this image and copyright information in PMC

Comment in

References

    1. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. Wolters Kluwer/Lippincott Williams & Wilkins Health; Philadelphia: 2011.
    1. Wang CC, Schulz MD. Ewing's sarcoma; a study of fifty cases treated at the Massachusetts General Hospital, 1930-1952 inclusive. N Engl J Med. 1953;248(14):571–576. - PubMed
    1. Dahlin DC, Coventry MB, Scanlon PW. Ewing's sarcoma. A critical analysis of 165 cases. The Journal of bone and joint surgery American volume. 1961;43-A:185–192. - PubMed
    1. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(33):4148–4154. - PMC - PubMed
    1. Felgenhauer JL, Nieder ML, Krailo MD, et al. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893. Pediatric blood & cancer. 2013;60(3):409–414. - PMC - PubMed

Publication types

MeSH terms

Substances